J&J, partners speed pace of Ebola prime-boost vaccine
This article was originally published in Scrip
Executive Summary
Johnson & Johnson and its partners are the latest to quicken the pace of a product against the Ebola virus, in this case, accelerating the development program for a prime-boost vaccine regimen, which is being funded in part by the National Institute of Allergy and Infectious Diseases (NIAID), part of the US National Institutes of Health (NIH).